GILD Q1 2026 Earnings Analysis

Absolutely, Alex! Let's start with the headline numbers because they're quite strong. Total product sales hit $6.9 billion, up 5% year-over-year. But here's the kicker - if you exclude their COVID drug Veklury, their base business grew 8% to $6.8 billion. That's solid growth for a company Gilead's size.

The HIV business is absolutely on fire. They raised their HIV growth expectations from 6% to 8% for the full year, and get this - their PrEP drug Yes2Go, which prevents HIV, is now expected to hit $1 billion in sales. That would make it a blockbuster drug in just its first full year on the market!

It really is a multi-pronged success story. Their flagship HIV treatment Biktarvy continues to dominate with over 52% market share in the U.S. - that's a drug pulling in $3.4 billion in the quarter alone. But the real star is Yes2Go, their twice-yearly injectable HIV prevention drug. Sales jumped 72% just from the previous quarter to $166 million.

Great question! Johanna Mercier, their commercial chief, mentioned some really encouraging metrics. They now have 95% insurance coverage with 95% of those having zero copay for patients. They're seeing strong uptake from both people switching from other drugs and completely new users. And perhaps most importantly, the "persistency" - meaning people coming back for their second injection - is looking really good.

This is where it gets really interesting from a strategic perspective. They closed three major deals: Arcellx for their cancer cell therapy anitocel, they're buying Tubulis for their antibody-drug conjugate technology, and Oral Medicines for autoimmune treatments. The total upfront cost? About $11.5 billion.

Well, it's definitely impacting their near-term earnings - they're actually projecting a loss per share for 2026 because of these upfront costs. But management seemed confident these are strategic investments for the long term. The Arcellx deal brings them anitocel, which they believe could be best-in-class for multiple myeloma. And Tubulis gives them next-generation cancer drug technology that goes beyond their current Trodelvy franchise.

Trodelvy is growing nicely - up 37% year-over-year to $402 million. They're expecting regulatory decisions this year that could expand its use to first-line breast cancer treatment, which would be a significant market expansion. The NCCN medical guidelines have already given it their top recommendation, so physicians are already starting to use it more broadly.

Absolutely! They're developing a once-yearly version of lenacapavir for HIV prevention. They've completed enrollment in their Phase 3 trial and expect approval by 2028. If successful, imagine - one shot per year to prevent HIV. That could be transformational for public health, especially in underserved communities.

That's a great point. Despite all these acquisitions, they still returned over 60% of their free cash flow to shareholders through dividends and buybacks - about $1.4 billion in the quarter. CFO Andy Dickinson emphasized they're maintaining financial discipline while making these strategic investments.

There are several key catalysts coming up. In August, they expect FDA approval for Biclen, a new once-daily HIV treatment. In December, they're expecting approval for anitocel in multiple myeloma. Plus, they have multiple Phase 3 trial readouts expected in the second half of the year across HIV, cancer, and liver disease programs.

Management emphasized they can absorb the incremental costs from these deals while maintaining strong margins. They delivered a 47% operating margin this quarter and expect the revenue growth to essentially offset the additional expenses on an earnings-per-share basis, excluding those big upfront acquisition costs.

I think this quarter really showcases Gilead's evolution. They're not just an HIV company anymore - they're building a diversified portfolio across HIV, oncology, and liver disease, with potential expansion into autoimmune conditions. The HIV business remains a cash cow that's funding innovation in other areas. Yes2Go's success shows they can still innovate in their core HIV business, while these acquisitions position them for growth in new therapeutic areas.

The main concern is execution risk. They're integrating three major acquisitions simultaneously while launching multiple new products. Management acknowledged they're less likely to pursue more large acquisitions this year while they focus on integration. Also, their cell therapy business was down 12% year-over-year, showing that not every franchise is growing.

Gilead seems to be positioning itself as a growth company again after years of being seen as a value play. The HIV business provides a stable foundation with limited patent cliffs until 2036, while these acquisitions could drive the next wave of growth. The key will be successful execution of these new product launches and pipeline development.

This feels like an inflection point for Gilead. They're making bold moves to reinvent themselves beyond just HIV, while their core business is actually accelerating. The next few quarters will be crucial as we see if these big bets pay off. Everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.